CHARLOTTE, N.C.—A novel, proprietary immunoglobulin G–based elimination diet can improve outcomes in patients with irritable bowel syndrome, according to the results of a prospective multicenter trial presented at the 2022 annual meeting of the American College of Gastroenterology (abstract S521).
The elimination diet yielded a greater change from baseline than a sham diet, on global end points of IBS, including the Global Improvement Scale (GIS) and the Subject Global Assessment of